| Diabetic neuropathy EL Feldman, BC Callaghan, R Pop-Busui, DW Zochodne, DE Wright, ... Nature reviews Disease primers 5 (1), 41, 2019 | 1772 | 2019 |
| Diabetic neuropathy: clinical manifestations and current treatments BC Callaghan, HT Cheng, CL Stables, AL Smith, EL Feldman The lancet NEUROLOGY 11 (6), 521-534, 2012 | 1480 | 2012 |
| Enhanced glucose control for preventing and treating diabetic neuropathy BC Callaghan, AA Little, EL Feldman, RAC Hughes Cochrane database of systematic reviews, 2012 | 830 | 2012 |
| Diabetic neuropathy: cellular mechanisms as therapeutic targets AM Vincent, BC Callaghan, AL Smith, EL Feldman Nature Reviews Neurology 7 (10), 573-583, 2011 | 674 | 2011 |
| Neurological consequences of obesity P D O'Brien, LM Hinder, BC Callaghan, EL Feldman The Lancet Neurology 16 (6), 465-477, 2017 | 516 | 2017 |
| Likelihood of seizure remission in an adult population with refractory epilepsy BC Callaghan, K Anand, D Hesdorffer, WA Hauser, JA French Annals of neurology 62 (4), 382-389, 2007 | 407 | 2007 |
| Distal symmetric polyneuropathy: a review BC Callaghan, RS Price, EL Feldman Jama 314 (20), 2172-2181, 2015 | 356 | 2015 |
| The endoribonuclease activity of mammalian IRE1 autoregulates its mRNA and is required for the unfolded protein response W Tirasophon, K Lee, B Callaghan, A Welihinda, RJ Kaufman Genes & development 14 (21), 2725-2736, 2000 | 351 | 2000 |
| Painful diabetic neuropathy A Peltier, SA Goutman, BC Callaghan Bmj 348, 2014 | 278 | 2014 |
| Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark ST Andersen, DR Witte, EM Dalsgaard, H Andersen, P Nawroth, ... Diabetes care 41 (5), 1068-1075, 2018 | 256 | 2018 |
| Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status BC Callaghan, R Xia, M Banerjee, N de Rekeneire, TB Harris, ... Diabetes care 39 (5), 801-807, 2016 | 230 | 2016 |
| Association between metabolic syndrome components and polyneuropathy in an obese population BC Callaghan, R Xia, E Reynolds, M Banerjee, AE Rothberg, CF Burant, ... JAMA neurology 73 (12), 1468-1476, 2016 | 226 | 2016 |
| Diabetes and obesity are the main metabolic drivers of peripheral neuropathy BC Callaghan, LL Gao, Y Li, X Zhou, E Reynolds, M Banerjee, ... Annals of clinical and translational neurology 5 (4), 397-405, 2018 | 221 | 2018 |
| Diabetic neuropathy: one disease or two? BC Callaghan, J Hur, EL Feldman Current opinion in neurology 25 (5), 536-541, 2012 | 220 | 2012 |
| Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments MA Elafros, H Andersen, DL Bennett, MG Savelieff, V Viswanathan, ... The Lancet Neurology 21 (10), 922-936, 2022 | 205 | 2022 |
| Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis C Figueroa-Romero, J Hur, DE Bender, CE Delaney, MD Cataldo, ... PloS one 7 (12), e52672, 2012 | 196 | 2012 |
| 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2023 NA ElSayed, G Aleppo, VR Aroda, RR Bannuru, FM Brown, D Bruemmer, ... Diabetes care 46 (Supplement_1), S203-S215, 2023 | 190 | 2023 |
| Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management TS Jensen, P Karlsson, SS Gylfadottir, ST Andersen, DL Bennett, ... Brain 144 (6), 1632-1645, 2021 | 190 | 2021 |
| Remission and relapse in a drug‐resistant epilepsy population followed prospectively B Callaghan, M Schlesinger, W Rodemer, J Pollard, D Hesdorffer, ... Epilepsia 52 (3), 619-626, 2011 | 190 | 2011 |
| Association of environmental toxins with amyotrophic lateral sclerosis FC Su, SA Goutman, S Chernyak, B Mukherjee, BC Callaghan, ... JAMA neurology 73 (7), 803-811, 2016 | 178 | 2016 |
